Public call for the selection of project proposals to be financed within the research activities of Spoke n. 6 “RNA drug development”

September 5, 2024

FORM FACILITATION

Contribution/Repayable fund

REGIONS

Piedmont, Lombardy, Valle d'Aosta/Vallée d'Aoste, Liguria, Abruzzo, Molise, Basilicata, Calabria, Campania, Puglia, Sicily, Trentino-Alto Adige/Südtirol, Veneto, Sardinia, Tuscany, Friuli-Venezia Giulia, Emilia- Romagna, Umbria, Marche, Lazio

SECTOR

Chemistry and Pharmaceuticals, Health

ALLOWED EXPENSE

4639617 €

INCENTIVE STATUS

CLOSED

OPENING DATE

CLOSING DATE

December 20, 2023
January 31, 2024

NOTES

No additional notes
Share fact sheet

Things

Public call for the selection of project proposals to be financed within the research activities of Spoke n. 6 "RNA drug development", referred to in the research program of the National center for the development of gene therapy and drugs with RNA technology "National center for gene therapy and drugs based on RNA Technology (cn rna & gene therapy)", drawing on the resources of the National Recovery and Resilience Plan (PNRR), mission 4 "education and research", component 2 "from research to business", Investment line 1.4 “Strengthening research structures and creation of national R&D champions on some key enabling technologies”. Funded by the European Union – NEXTGENERATIONEUProject CN00000041CUP B83C22002860006 

Who is it aimed at?

The following can participate in this Call: ● Micro, Small and Medium Enterprises (MSMEs), external to the National Center and competing in single mode, having the dimensional parameters referred to in Annex I of REG (EC) no. 800/2008 of the Commission of 6 August 2008 (General Block Exemption Regulation) in OJEU L 214 of 9.8.2008, including innovative start-ups; ● Large Enterprises (GI), external to the National Center and which compete in single mode; ● Public research bodies and institutions, including universities, and the bodies referred to in Legislative Decree no. 218/2016 (https:// www.mur.gov.it/it/aree-tematiche/ricerca/il-sistema-della-ricerca/enti-diricerca-pubblici);● Scientific Hospitalization and Care Institutes – IRCCS, which are public or private in nature; ● Entities referred to in the Third Sector Code - Legislative Decree 3 July 2017 n.117 and subsequent amendments. Eligible subjects can submit contribution requests exclusively in single form. In line with the provisions of the art. 5 of Public Notice no. 3138 of 12/16/2021 (paragraph 2 "The notices are issued for the granting of funding to subjects external to the CN for research activities consistent with the aforementioned Programme"), the participation in this notice of subjects (public or private) is excluded ) already participants of the National Center referred to in art. 1, as well as companies that qualify as their subsidiaries or associated companies pursuant to art. 2359 cod. civil 

What does it predict

The project proposals presented will concern research activities consistent with the CN RNA & Gene Therapy research program and with the specific research objectives of Spoke 6. The objective of this call is to reach public bodies and private entities strongly interested in introducing significant innovations in relation to products and processes. In particular, the Spoke has identified types of activities and areas of intervention envisaged by the following Article 3. The call therefore intends to expand the research network established by the members of the National Center and finance new entities that can obtain results that are integrated into the research program , expanding its technological skills and accelerating the process of designing and developing new treatments based on the Key Enabling Technologies covered by the CN RNA & Gene Therapy. 

Objective – Purpose

Innovation and research

Form – Facilitation

Contribution/Repayable fund

Minimum Allowable Expenditure

4639617 €

Maximum Allowable Expenditure

4639617 €

Allowed Costs

Buildings and land, Professional training, Personnel costs, Raw materials, consumables and goods, Services, patents and licenses, General expenses/other charges, Plant/Machinery/Equipment

Maximum grantable benefit

4639620 €
Subject type
Company, University/Research Institution

Dimension

Microenterprise, Medium Enterprise, Large Enterprise, Small Enterprise

Activity sector

Chemistry and Pharmaceuticals, Health

ATECO

All economic sectors eligible to receive aid

Regions

Piedmont, Lombardy, Valle d'Aosta/Vallée d'Aoste, Liguria, Abruzzo, Molise, Basilicata, Calabria, Campania, Puglia, Sicily, Trentino-Alto Adige/Südtirol, Veneto, Sardinia, Tuscany, Friuli-Venezia Giulia, Emilia- Romagna, Umbria, Marche, Lazio

Managing entity

National Research Council - CNR

Primary regulatory basis

MUR Directorial Decree n. 3138 of 16 December 2021 and subsequent addition to DD n. 3175 of 18 December 2021, registered at the Court of Auditors on 15/01/2022 n. 100

Implementation measure

MUR Directorial Decree n. 3138 of 16 December 2021 and subsequent addition to DD n. 3175 of 18 December 2021, registered at the Court of Auditors on 15/01/2022 n. 100

Incentive allocation

4639617 €

Reference site

https://archive.urp.cnr.it/copertine/formazione/form_concorsi/concorsi2023/IGM_CN_MRNA_Spoke_6.pdf

Is this the right announcement for you?

Let's find out together, fill out the form and request a free consultation